Summary
Biogen Idec Inc. (BIIB) filed its quarterly report on Form 10-Q for the period ended September 30, 2004. The report details the company's financial performance and condition, highlighting its status as an accelerated filer. Investors should note that the company has filed all required reports for the preceding 12 months and has been subject to such filing requirements for the past 90 days, indicating a commitment to timely disclosure. This filing provides a snapshot of Biogen Idec's financial health during the third quarter of 2004. While specific revenue and profit figures are not detailed in this excerpt, the report's structure indicates a thorough review of its income statement, balance sheet, and cash flow statement. Investors should look to the detailed financial statements and Management's Discussion and Analysis (MD&A) within the full report for insights into sales trends, profitability drivers, and the company's operational efficiency.
Key Highlights
- 1Biogen Idec Inc. filed its 10-Q report for the quarterly period ended September 30, 2004.
- 2The company is classified as an accelerated filer, meeting the criteria for expedited reporting.
- 3Biogen Idec has met all SEC filing requirements for the preceding 12 months and the most recent 90-day period.
- 4The report includes unaudited Condensed Consolidated Statements of Income, Balance Sheets, and Cash Flows.
- 5Detailed notes to the financial statements are provided for a comprehensive understanding of the financial data.
- 6Management's Discussion and Analysis (MD&A) offers insights into the company's financial condition and operational results.
- 7The report confirms 333,552,272 shares of Common Stock outstanding as of October 1, 2004.